Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01867125




Registration number
NCT01867125
Ethics application status
Date submitted
29/05/2013
Date registered
3/06/2013
Date last updated
19/05/2017

Titles & IDs
Public title
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
Scientific title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
Secondary ID [1] 0 0
2013-000175-33
Secondary ID [2] 0 0
GB28688
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Lebrikizumab
Treatment: Drugs - Placebo

Experimental: Lebrikizumab (125 mg) - Participants will receive SC injection of lebrikizumab (125 milligrams \[mg\]) every 4 weeks for 104 weeks.

Experimental: Lebrikizumab (37.5 mg) - Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.

Placebo comparator: Placebo - Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.


Treatment: Drugs: Lebrikizumab
Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.

Treatment: Drugs: Placebo
Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Rate of Asthma Exacerbations During the 52-Week Placebo-Controlled Period
Timepoint [1] 0 0
Baseline up to 52 weeks
Secondary outcome [1] 0 0
Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Timepoint [1] 0 0
Baseline, Week 52
Secondary outcome [2] 0 0
Time to First Asthma Exacerbation
Timepoint [2] 0 0
Baseline up to 52 weeks
Secondary outcome [3] 0 0
Change From Baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ) Score
Timepoint [3] 0 0
Baseline, Week 52
Secondary outcome [4] 0 0
Change from Baseline In Asthma Rescue Medication (Number of Puffs or Nebulized Treatments)
Timepoint [4] 0 0
Baseline, Week 52
Secondary outcome [5] 0 0
Rate of Urgent Asthma-Related Urgent Health Care Utilization
Timepoint [5] 0 0
Baseline up to Week 52
Secondary outcome [6] 0 0
Percentage of Participants With Anti-Therapeutic Antibodies to Lebrikizumab
Timepoint [6] 0 0
Baseline up to Week 124 (assessed at Baseline, Weeks 4, 12, 24, 36, 52, 64, 76, 92, 104, 112, and 124)
Secondary outcome [7] 0 0
Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score
Timepoint [7] 0 0
Baseline, Week 52
Secondary outcome [8] 0 0
Percentage of Participants With Adverse Events
Timepoint [8] 0 0
Baseline, Week 124
Secondary outcome [9] 0 0
Minimum Serum Concentration (Cmin) of Lebrikizumab
Timepoint [9] 0 0
Predose (0 hour) on Weeks 4, 12, 24, 36, and 52

Eligibility
Key inclusion criteria
* Asthma diagnosis for greater than equal to (>/=) 12 months prior to Visit 1
* Bronchodilator response at Visit 1, 2, or 3
* Pre-bronchodilator FEV1 of 40 percent (%) - 80% predicted at both Visits 2 and 3
* On ICS therapy at a total daily dose of 500-2000 micrograms (mcg) of fluticasone propionate dry powder inhaler (DPI) or equivalent for >/=6 months prior to Visit 1
* On an eligible second controller medication (long-acting beta-agonist [LABA], leukotriene receptor antagonist [LTRA], long-acting muscarinic antagonist [LAMA], or theophylline) for 6 months prior to Visit 1
* Uncontrolled asthma at Visit 1 and/or Visit 2, and at Visit 3
* Chest X-ray or computed tomography (CT) scan within 3 months prior to Visit 1 or chest X-ray during the screening period (prior to Visit 3) confirming the absence of other clinically significant lung disease
* Demonstrated adherence with controller medication during the screening period
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* History of severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection
* Maintenance oral corticosteroid therapy within 3 months of Visit 1
* Treatment with systemic (oral, intravenous [IV], or intramuscular [IM]) corticosteroids within 4 weeks prior to Visit 1 or during the screening period
* Treatment with intra-articular corticosteroids within 4 weeks prior to Visit 1 or during the screening period or anticipated need for intra-articular corticosteroids during the course of the study
* Infection requiring hospital admission for >/=24 hours or requiring treatment with IV or IM antibiotics within 4 weeks prior to Visit 1 or during screening; Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening; Active infection that required treatment with oral antibiotics within 2 weeks prior to Visit 1 or during screening; Active parasitic infection or Listeria monocytogenes infection within 6 months prior to Visit 1 or during screening
* Active tuberculosis requiring treatment within 12 months prior to Visit 1
* Known immunodeficiency, including, but not limited to, human immunodeficiency virus (HIV) infection
* Evidence of acute or chronic hepatitis or known liver cirrhosis
* History of interstitial lung disease, chronic obstructive pulmonary disease (COPD), or other clinically significant lung disease other than asthma
* Known current malignancy or current evaluation for potential malignancy
* Current smoker or former smoker with a history of greater than (>) 10 pack-years
* History of alcohol or drug abuse
* Past and/or current use of any anti-interleukin (IL)-13 or anti-IL-4/IL-13 therapy, including lebrikizumab
* Use of other monoclonal antibody therapy, including omalizumab, within 6 months or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
* Initiation of or change in allergen immunotherapy within 3 months prior to Visit 1 or during screening

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
31/07/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
2/01/2017
Sample size
Target
Accrual to date
Final
1081
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Liverpool Hospital - Liverpool BC
Recruitment hospital [2] 0 0
St. Vincent's Hospital Melbourne - Fitzroy
Recruitment hospital [3] 0 0
Box Hill Hospital; Eastern Clinical Research Unit - Box Hill
Recruitment hospital [4] 0 0
Western Hospital - Footscray
Recruitment hospital [5] 0 0
The Lung Institute of Western Australia; Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 0 0
1871 - Liverpool BC
Recruitment postcode(s) [2] 0 0
3065 - Fitzroy
Recruitment postcode(s) [3] 0 0
3128 - Box Hill
Recruitment postcode(s) [4] 0 0
3011 - Footscray
Recruitment postcode(s) [5] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Montana
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
Nevada
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Oklahoma
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
Rhode Island
Country [24] 0 0
United States of America
State/province [24] 0 0
South Carolina
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
United States of America
State/province [27] 0 0
Washington
Country [28] 0 0
United States of America
State/province [28] 0 0
Wisconsin
Country [29] 0 0
Argentina
State/province [29] 0 0
Buenos Aires
Country [30] 0 0
Argentina
State/province [30] 0 0
Mar Del Plata
Country [31] 0 0
Argentina
State/province [31] 0 0
Quilmes
Country [32] 0 0
Argentina
State/province [32] 0 0
San Miguel de Tucuman
Country [33] 0 0
Belgium
State/province [33] 0 0
Bruxelles
Country [34] 0 0
Belgium
State/province [34] 0 0
Gent
Country [35] 0 0
Canada
State/province [35] 0 0
Alberta
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec
Country [38] 0 0
Chile
State/province [38] 0 0
Santiago
Country [39] 0 0
Chile
State/province [39] 0 0
Valparaiso
Country [40] 0 0
Colombia
State/province [40] 0 0
Bogota DC
Country [41] 0 0
Czechia
State/province [41] 0 0
Jablonec Nad Nisou
Country [42] 0 0
Czechia
State/province [42] 0 0
Jindrichuv Hradec
Country [43] 0 0
Czechia
State/province [43] 0 0
Ostrava - Poruba
Country [44] 0 0
Czechia
State/province [44] 0 0
Teplice
Country [45] 0 0
France
State/province [45] 0 0
Lille
Country [46] 0 0
France
State/province [46] 0 0
Marseille
Country [47] 0 0
France
State/province [47] 0 0
Montpellier
Country [48] 0 0
France
State/province [48] 0 0
Nantes
Country [49] 0 0
France
State/province [49] 0 0
Strabourg
Country [50] 0 0
Germany
State/province [50] 0 0
Berlin
Country [51] 0 0
Germany
State/province [51] 0 0
Wiesloch
Country [52] 0 0
Hungary
State/province [52] 0 0
Debrecen
Country [53] 0 0
Hungary
State/province [53] 0 0
Gyor
Country [54] 0 0
Hungary
State/province [54] 0 0
Szeged
Country [55] 0 0
Israel
State/province [55] 0 0
Ashkelon
Country [56] 0 0
Israel
State/province [56] 0 0
Haifa
Country [57] 0 0
Israel
State/province [57] 0 0
Jerusalem
Country [58] 0 0
Israel
State/province [58] 0 0
Kfar Saba
Country [59] 0 0
Israel
State/province [59] 0 0
Rehovot
Country [60] 0 0
Italy
State/province [60] 0 0
Calabria
Country [61] 0 0
Italy
State/province [61] 0 0
Emilia-Romagna
Country [62] 0 0
Italy
State/province [62] 0 0
Marche
Country [63] 0 0
Italy
State/province [63] 0 0
Puglia
Country [64] 0 0
Italy
State/province [64] 0 0
Toscana
Country [65] 0 0
Italy
State/province [65] 0 0
Veneto
Country [66] 0 0
Japan
State/province [66] 0 0
Aichi
Country [67] 0 0
Japan
State/province [67] 0 0
Amagasaki-shi
Country [68] 0 0
Japan
State/province [68] 0 0
Fukuoka-shi
Country [69] 0 0
Japan
State/province [69] 0 0
Higashiibaraki-gun
Country [70] 0 0
Japan
State/province [70] 0 0
Hiroshima
Country [71] 0 0
Japan
State/province [71] 0 0
Hokkaido
Country [72] 0 0
Japan
State/province [72] 0 0
Iwate
Country [73] 0 0
Japan
State/province [73] 0 0
Kanagawa
Country [74] 0 0
Japan
State/province [74] 0 0
Kiyose-shi
Country [75] 0 0
Japan
State/province [75] 0 0
Kochi
Country [76] 0 0
Japan
State/province [76] 0 0
Kodaira-shi
Country [77] 0 0
Japan
State/province [77] 0 0
Kokubunji-shi
Country [78] 0 0
Japan
State/province [78] 0 0
Koshigaya-shi
Country [79] 0 0
Japan
State/province [79] 0 0
Mizunami-shi
Country [80] 0 0
Japan
State/province [80] 0 0
Nagaoka-shi
Country [81] 0 0
Japan
State/province [81] 0 0
Niigata-shi
Country [82] 0 0
Japan
State/province [82] 0 0
Osaka
Country [83] 0 0
Japan
State/province [83] 0 0
Ota-ku
Country [84] 0 0
Japan
State/province [84] 0 0
Sapporo-shi
Country [85] 0 0
Japan
State/province [85] 0 0
Tokyo
Country [86] 0 0
Japan
State/province [86] 0 0
Toshima
Country [87] 0 0
Japan
State/province [87] 0 0
Yoshida-gun
Country [88] 0 0
Korea, Republic of
State/province [88] 0 0
Gyeonggi-do
Country [89] 0 0
Korea, Republic of
State/province [89] 0 0
Seoul
Country [90] 0 0
Korea, Republic of
State/province [90] 0 0
Wonju
Country [91] 0 0
Mexico
State/province [91] 0 0
Guadalajara
Country [92] 0 0
Mexico
State/province [92] 0 0
Zapopan
Country [93] 0 0
New Zealand
State/province [93] 0 0
Auckland
Country [94] 0 0
New Zealand
State/province [94] 0 0
Dunedin
Country [95] 0 0
New Zealand
State/province [95] 0 0
Tauranga
Country [96] 0 0
Poland
State/province [96] 0 0
Bialystok
Country [97] 0 0
Poland
State/province [97] 0 0
Krakow
Country [98] 0 0
Poland
State/province [98] 0 0
Kraków
Country [99] 0 0
Poland
State/province [99] 0 0
Lódz
Country [100] 0 0
Poland
State/province [100] 0 0
Poznan
Country [101] 0 0
Poland
State/province [101] 0 0
Proszowice
Country [102] 0 0
Poland
State/province [102] 0 0
Skarzysko-Kamienna
Country [103] 0 0
Poland
State/province [103] 0 0
Warszawa
Country [104] 0 0
Poland
State/province [104] 0 0
Wroclaw
Country [105] 0 0
Romania
State/province [105] 0 0
Bucharest
Country [106] 0 0
Romania
State/province [106] 0 0
Cluj-Napoca
Country [107] 0 0
Romania
State/province [107] 0 0
Craiova
Country [108] 0 0
Romania
State/province [108] 0 0
Timisoara
Country [109] 0 0
Russian Federation
State/province [109] 0 0
Kemerovo
Country [110] 0 0
Russian Federation
State/province [110] 0 0
Moscow
Country [111] 0 0
Russian Federation
State/province [111] 0 0
Novosibirsk
Country [112] 0 0
Russian Federation
State/province [112] 0 0
Ryazan
Country [113] 0 0
Russian Federation
State/province [113] 0 0
Saint Petersburg
Country [114] 0 0
Russian Federation
State/province [114] 0 0
Saint-Petersburg
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Smolensk
Country [116] 0 0
Russian Federation
State/province [116] 0 0
St Petersburg
Country [117] 0 0
Russian Federation
State/province [117] 0 0
St. Petersburg
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Tomsk
Country [119] 0 0
Serbia
State/province [119] 0 0
Belgrade
Country [120] 0 0
Slovakia
State/province [120] 0 0
Bardejov
Country [121] 0 0
Slovakia
State/province [121] 0 0
Bratislava
Country [122] 0 0
Slovakia
State/province [122] 0 0
Spisska Nova Ves
Country [123] 0 0
South Africa
State/province [123] 0 0
Cape Town
Country [124] 0 0
South Africa
State/province [124] 0 0
Durban
Country [125] 0 0
South Africa
State/province [125] 0 0
Gatesville
Country [126] 0 0
South Africa
State/province [126] 0 0
Johannesburg
Country [127] 0 0
South Africa
State/province [127] 0 0
Pretoria
Country [128] 0 0
Spain
State/province [128] 0 0
Alava
Country [129] 0 0
Spain
State/province [129] 0 0
Barcelona
Country [130] 0 0
Spain
State/province [130] 0 0
Madrid
Country [131] 0 0
Spain
State/province [131] 0 0
Sevilla
Country [132] 0 0
Spain
State/province [132] 0 0
Valencia
Country [133] 0 0
Turkey
State/province [133] 0 0
Ankara
Country [134] 0 0
Turkey
State/province [134] 0 0
Bursa
Country [135] 0 0
Turkey
State/province [135] 0 0
Canakkale
Country [136] 0 0
Turkey
State/province [136] 0 0
Izmir
Country [137] 0 0
Turkey
State/province [137] 0 0
Kirikkale
Country [138] 0 0
Turkey
State/province [138] 0 0
Mersin
Country [139] 0 0
Ukraine
State/province [139] 0 0
Dnepropetrovsk
Country [140] 0 0
Ukraine
State/province [140] 0 0
Donetsk
Country [141] 0 0
Ukraine
State/province [141] 0 0
Ivano-Frankivsk
Country [142] 0 0
Ukraine
State/province [142] 0 0
Kharkiv
Country [143] 0 0
Ukraine
State/province [143] 0 0
Kyiv
Country [144] 0 0
Ukraine
State/province [144] 0 0
Lviv
Country [145] 0 0
Ukraine
State/province [145] 0 0
Vinnytsya
Country [146] 0 0
Ukraine
State/province [146] 0 0
Yevpatoriya
Country [147] 0 0
Ukraine
State/province [147] 0 0
Zaporizhzhia
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Chertsey
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Cottingham
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Dundee
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Leeds
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Teesside

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid (ICS) therapy and at least one second controller medication. Participants will be randomized in 1:1:1 ratio to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered subcutaneously (SC) every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. During double-blind active treatment extension period, all participants will receive SC injection of lebrikizumab from Week 53 to Week 104. The anticipated time on study treatment is 104 weeks. After study treatment, all participants will complete a 20-week safety follow-up.
Trial website
https://clinicaltrials.gov/study/NCT01867125
Trial related presentations / publications
Chen M, Shepard K 2nd, Yang M, Raut P, Pazwash H, Holweg CTJ, Choo E. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy. 2021 Apr;51(4):546-555. doi: 10.1111/cea.13790. Epub 2021 Jan 7.
N Bauer R, Yang X, L Staton T, Olsson J, Holweg CTJ, R Arron J, Matthews JG, Choy DF. Seasonal variability of lung function and Asthma Quality of Life Questionnaire Scores in adults with uncontrolled asthma. BMJ Open Respir Res. 2019 Nov 11;6(1):e000406. doi: 10.1136/bmjresp-2019-000406. eCollection 2019.
Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 Oct;4(10):781-796. doi: 10.1016/S2213-2600(16)30265-X. Epub 2016 Sep 5.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01867125